Tweet
Illumina, Inc. (NASDAQ:ILMN) SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $331.39, for a total transaction of $3,313,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website .
Mostafa Ronaghi also recently made the following trade(s): Get Illumina alerts: On Tuesday, July 10th, Mostafa Ronaghi sold 7,500 shares of Illumina stock. The shares were sold at an average price of $288.89, for a total transaction of $2,166,675.00. On Monday, June 11th, Mostafa Ronaghi sold 10,500 shares of Illumina stock. The shares were sold at an average price of $284.83, for a total transaction of $2,990,715.00. On Wednesday, May 16th, Mostafa Ronaghi sold 10,000 shares of Illumina stock. The shares were sold at an average price of $267.71, for a total transaction of $2,677,100.00.
Shares of ILMN stock opened at $326.98 on Friday. Illumina, Inc. has a 12-month low of $189.15 and a 12-month high of $341.08. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.44 and a current ratio of 2.74. The company has a market capitalization of $48.55 billion, a P/E ratio of 81.75, a P/E/G ratio of 2.76 and a beta of 0.97. Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.11 by $0.32. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The company had revenue of $830.00 million for the quarter, compared to analysts' expectations of $786.88 million. During the same quarter last year, the company posted $0.82 earnings per share. The firm's quarterly revenue was up 25.4% on a year-over-year basis. equities analysts predict that Illumina, Inc. will post 5.41 EPS for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Kaizen Advisory LLC raised its position in Illumina by 161.0% in the second quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company's stock worth $103,000 after acquiring an additional 227 shares during the period. Moneta Group Investment Advisors LLC raised its position in Illumina by 2,670.0% in the second quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company's stock worth $107,000 after acquiring an additional 9,345 shares during the period. Sun Life Financial INC raised its position in Illumina by 152.5% in the second quarter. Sun Life Financial INC now owns 399 shares of the life sciences company's stock worth $111,000 after acquiring an additional 241 shares during the period. Harvest Fund Management Co. Ltd bought a new position in Illumina in the first quarter worth approximately $113,000. Finally, Migdal Insurance & Financial Holdings Ltd. raised its position in Illumina by 3,192.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company's stock worth $120,000 after acquiring an additional 415 shares during the period. Institutional investors and hedge funds own 90.80% of the company's stock.
A number of equities research analysts have recently commented on ILMN shares. Canaccord Genuity reiterated a "buy" rating and set a $340.00 price target (up previously from $330.00) on shares of Illumina in a report on Friday, July 27th. Barclays upgraded shares of Illumina from an "equal weight" rating to an "overweight" rating and set a $235.00 price target on the stock in a report on Monday, May 7th. BTIG Research reiterated a "hold" rating on shares of Illumina in a report on Wednesday, April 25th. Robert W. Baird raised their target price on shares of Illumina from $261.00 to $271.00 and gave the stock an "outperform" rating in a report on Wednesday, April 25th. Finally, Deutsche Bank raised their target price on shares of Illumina from $280.00 to $330.00 and gave the stock a "buy" rating in a report on Tuesday, July 31st. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of "Buy" and a consensus price target of $303.53.
About Illumina
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array